SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY ARTICLE M impact

Novo Nordisk CEO to face pressure on strategy

CEO Mike Doustdar will face pressure Monday to outline how Novo Nordisk will compete with US rival Eli Lilly and boost growth beyond Wegovy.

LLYNOVOB

Wegovy-maker Novo Nordisk's OMXCOP:NOVO_B CEO Mike Doustdar is set to face pressure on Monday to outline his strategy for competing with U.S. rival Eli Lilly NYSE:LLY and explain how he plans to lift growth beyond the blockbuster weight-loss drug. Novo Nordisk benefited from a surge in demand after...

Related stories